Login to Your Account



Medivir's Stock Jumps On $105M BMS HIV Agreement

By Cormac Sheridan


Wednesday, September 20, 2006
Medivir AB took another step toward its goal of divesting its polymerase inhibitor assets before year-end by entering a pact with Bristol-Myers Squibb Co. to develop and commercialize its preclinical HIV drug candidate, MIV-170. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription